HN2001000277A - PIRROLO [2,1 - a] DIHIDROISOQUINOLINAS - Google Patents

PIRROLO [2,1 - a] DIHIDROISOQUINOLINAS

Info

Publication number
HN2001000277A
HN2001000277A HN2001000277A HN2001000277A HN2001000277A HN 2001000277 A HN2001000277 A HN 2001000277A HN 2001000277 A HN2001000277 A HN 2001000277A HN 2001000277 A HN2001000277 A HN 2001000277A HN 2001000277 A HN2001000277 A HN 2001000277A
Authority
HN
Honduras
Prior art keywords
pirrolo
dihydroisoquinolins
dihydroisoquinolines
phosphodiesterase
inhibitors
Prior art date
Application number
HN2001000277A
Other languages
English (en)
Spanish (es)
Inventor
Niewohner Ulrich
Bauser Marcus
Erguden Jens-Kerim
Flubacher Dietmar
Naab Paul
Reep Thorsten-Oliver
Stoltefub Juergen
Burkhardt Nils
Sewing Andrea
Schauer Michael
Schlemmer Karl-Heinz
Weber Olaf
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of HN2001000277A publication Critical patent/HN2001000277A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HN2001000277A 2000-12-13 2001-12-12 PIRROLO [2,1 - a] DIHIDROISOQUINOLINAS HN2001000277A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25520600P 2000-12-13 2000-12-13
US31031201P 2001-08-06 2001-08-06

Publications (1)

Publication Number Publication Date
HN2001000277A true HN2001000277A (es) 2002-01-30

Family

ID=26944520

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2001000277A HN2001000277A (es) 2000-12-13 2001-12-12 PIRROLO [2,1 - a] DIHIDROISOQUINOLINAS

Country Status (10)

Country Link
US (1) US6930114B2 (enExample)
EP (1) EP1347973A1 (enExample)
JP (1) JP2004517843A (enExample)
AU (1) AU2002227985A1 (enExample)
CA (1) CA2431326A1 (enExample)
HN (1) HN2001000277A (enExample)
PE (1) PE20021085A1 (enExample)
SV (1) SV2002000761A (enExample)
UY (1) UY27067A1 (enExample)
WO (1) WO2002048144A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236276A1 (en) * 2001-08-06 2003-12-25 Ulrich Niewohner Pyrrolo[2.1-a]isoquinoline derivatives
WO2003014115A1 (en) * 2001-08-06 2003-02-20 Bayer Aktiengesellschaft 3-substituted pyrrolo (2.1-a) isoquinoline derivatives
AU2002366362A1 (en) * 2001-12-18 2003-06-30 Bayer Aktiengesellschaft 2-substituted pyrrolo(2.1-a)isoquinolines against cancer
DE10230604A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
US8338420B1 (en) 2002-12-04 2012-12-25 Mitsubishi Tanabe Pharma Corporation Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
US7135480B2 (en) * 2002-12-12 2006-11-14 Cytovia, Inc. Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis
MXPA05013822A (es) * 2003-06-30 2006-02-28 Altana Pharma Ag Pirrolodihidroisoquinolinas utiles en el tratamiento del cancer.
ES2331519T3 (es) * 2003-06-30 2010-01-07 Nycomed Gmbh Derivados de pirrolo-dihidroisoquinolina como inhibidores de pde10.
DE602006006544D1 (de) * 2005-01-12 2009-06-10 Nycomed Gmbh Neue pyrrolodihydroisochinoline als pde10-inhibitoren
CA2595075A1 (en) * 2005-01-12 2006-07-20 Matthias Vennemann Pyrrolodihydroisoquinolines as antiproliferative agents
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
CA2654394A1 (en) * 2006-06-26 2008-01-03 Pfizer Products Inc. Tricyclic heteroaryl compounds as pde10 inhibitors
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
TW200944523A (en) * 2008-02-08 2009-11-01 Organon Nv (Dihydro)pyrrolo[2,1-a]isoquinolines
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2507244B1 (en) 2009-12-04 2014-11-05 Nerviano Medical Sciences S.r.l. Tricyclopyrazole derivatives
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2015006689A1 (en) 2013-07-12 2015-01-15 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression
GB202002926D0 (en) * 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE690792A (enExample) 1966-12-07 1967-05-16
FR7348M (enExample) * 1967-12-07 1969-10-13
US4719216A (en) 1983-06-23 1988-01-12 Mcneilab, Inc. Hexahydropyrrolo(2,1-A)isoquinoline derivatives as antidepressants
DE3401018A1 (de) 1984-01-13 1985-07-18 Boehringer Ingelheim KG, 6507 Ingelheim Verfahren zur herstellung von 5,6-dihydro-pyrrolo(2,1-a)isochinolinen
GB8718980D0 (en) 1987-08-11 1987-09-16 May & Baker Ltd Compositions of matter
IT1292092B1 (it) 1997-06-05 1999-01-25 Geange Ltd Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali
US6673564B2 (en) 1999-10-18 2004-01-06 Millennium Pharmaceuticals, Inc. Methods for using 22045, a human cyclic nucleotide phosphodiesterase

Also Published As

Publication number Publication date
CA2431326A1 (en) 2002-06-20
EP1347973A1 (en) 2003-10-01
WO2002048144A1 (en) 2002-06-20
AU2002227985A1 (en) 2002-06-24
US20040138249A1 (en) 2004-07-15
UY27067A1 (es) 2002-07-31
US6930114B2 (en) 2005-08-16
JP2004517843A (ja) 2004-06-17
SV2002000761A (es) 2002-12-02
PE20021085A1 (es) 2003-05-16

Similar Documents

Publication Publication Date Title
HN2001000277A (es) PIRROLO [2,1 - a] DIHIDROISOQUINOLINAS
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
AU3652102A (en) Compounds and their uses
ECSP034568A (es) Inhibidores de metaloproteinasa del tipo pirimidin 2,4,6-triona
PL360262A1 (pl) Kompozycje polimerycznych micelli
CR7182A (es) Benzoilsufanamidas y sulfonilbenzamidinas que se usan como agentes antitumorales
MXPA02007915A (es) Mediador de lipido activado por aspirina.
HN2000000137A (es) Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
CY1106366T1 (el) Ενωση λακταμης για την αναστολη της απελευθερωσης ή της συνθεσης βητα-αμυλοειδους πεπτιδιου
DE60218458D1 (de) Isochinolinon derivate als parp inhibitoren
HN2002000208A (es) 1-ALQUIL O 1 - CICLOALQUIL-TRIAZOLO [4.3 - a] QUINAZOLIN -5-ONAS COMO INHIBIDORES DE FOSFODIESTERASAS
MXPA03000263A (es) Correlacion del objetivo de fuentes multiples.
DK1224172T3 (da) Medikamenter til behandling af ondartede tumorer
MXPA04003886A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplasticos.
DE60228484D1 (de) Cytotoxische mittel
NI200300045A (es) Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
HN1998000091A (es) Inhibidores de la farnesil transferasa tratamiento del cancer.
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
ATE374203T1 (de) Therapeutische verbindungen und verfahren
MXPA04003910A (es) Uso de irbesartan para la preparacion de medicamentos que son utiles para la prevencion o tratamiento de hipertension pulmonar.
HRP20040186B1 (en) Use of lhrh-antagonists for the improvement of t-cell mediated immunity
NO20005548D0 (no) Mykobakterieinhibitorer
DE60111614D1 (de) Taxan-derivate für die behandlung von krebs
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων